For instance, one study describes sensitization of NSCLC by cetuximab-conjugated mesoporous silica NPs targeting EGFR and loaded with polo-like kinase 1 (Plk1) siRNA [173]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.